CPI, MicrofluidX, and the Cell and Gene Therapy Catapult (CGT Catapult) are collaborating on a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies. The technology has the potential to overcome a major bottleneck in the development of these novel treatments, and reduce the time and costs associated with bringing such therapies to market.   Cell and gene therapies are produced from inherently variable living cells. As such, it is highly challenging to achi...